Add to ORKGBackground: Phosphodiesterase type 5 (PDE5) hydrolyzes cyclic guanosine monophosphate in the lung, thereby modulating nitric oxide (NO)/cyclic guanosine monophosphatemediated pulmonary vasodilation. Inhibitors of PDE5 have been proposed for the treatment of pulmonary hypertension. In this study, we examined the pulmonary and systemic vasodilator properties of sildenafil, a novel selective PDE
Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosph...
javax.xml.bind.JAXBElement@6f8948ff Hypoxia represents both an outcome of cardiopulmonary diseases ...
Background—Phosphodiesterase type 5 (PDE5) inhibitors (eg, sildenafil) are a novel, orally active ap...
AbstractPulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent vasodilat...
AbstractPulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent vasodilat...
Chronic damage to pulmonary vessels leads to pulmonary hypertension (PH). Different forms of PH are ...
ObjectivesWe sought to compare the short-termimpact of three different phosphodiesterase-5 (PDE5) in...
RATIONALE: Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) are selective pulmonary vasodila...
SummarySildenafil and inhaled nitric oxide (iNO) relax smooth muscle by inhibiting the degradation a...
RATIONALE: Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) are selective pulmonary vasodila...
RATIONALE: Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) are selective pulmonary vasodila...
Pulmonary arterial hypertension is defined as a group of diseases characterized by a progressive inc...
Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosph...
javax.xml.bind.JAXBElement@6f8948ff Hypoxia represents both an outcome of cardiopulmonary diseases ...
Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosph...
Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosph...
javax.xml.bind.JAXBElement@6f8948ff Hypoxia represents both an outcome of cardiopulmonary diseases ...
Background—Phosphodiesterase type 5 (PDE5) inhibitors (eg, sildenafil) are a novel, orally active ap...
AbstractPulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent vasodilat...
AbstractPulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent vasodilat...
Chronic damage to pulmonary vessels leads to pulmonary hypertension (PH). Different forms of PH are ...
ObjectivesWe sought to compare the short-termimpact of three different phosphodiesterase-5 (PDE5) in...
RATIONALE: Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) are selective pulmonary vasodila...
SummarySildenafil and inhaled nitric oxide (iNO) relax smooth muscle by inhibiting the degradation a...
RATIONALE: Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) are selective pulmonary vasodila...
RATIONALE: Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) are selective pulmonary vasodila...
Pulmonary arterial hypertension is defined as a group of diseases characterized by a progressive inc...
Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosph...
javax.xml.bind.JAXBElement@6f8948ff Hypoxia represents both an outcome of cardiopulmonary diseases ...
Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosph...
Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosph...
javax.xml.bind.JAXBElement@6f8948ff Hypoxia represents both an outcome of cardiopulmonary diseases ...
Background—Phosphodiesterase type 5 (PDE5) inhibitors (eg, sildenafil) are a novel, orally active ap...